TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

Search

CSL Ltd

Închisă

SectorSectorul industrial

257.01 0.65

Rezumat

Modificarea prețului

24h

Curent

Minim

250.43

Maxim

257.24

Indicatori cheie

By Trading Economics

Venit

1.3B

2B

Vânzări

1.5B

8.2B

P/E

Medie Sector

28.972

33.198

EPS

1.831

Randament dividend

1.7

Marjă de profit

24.437

Angajați

32,698

EBITDA

1.5B

3.2B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+26.05% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.70%

2.54%

Data viitoare de dividende

9 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-14B

121B

Deschiderea anterioară

256.36

Închiderea anterioară

257.01

Sentimentul știrilor

By Acuity

34%

66%

121 / 468 Clasament în Industrials

CSL Ltd Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 feb. 2025, 21:55 UTC

Câștiguri

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb. 2025, 21:34 UTC

Câștiguri

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

12 aug. 2024, 23:23 UTC

Câștiguri

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12 aug. 2024, 22:49 UTC

Câștiguri

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

21 mar. 2025, 02:03 UTC

Market Talk

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 feb. 2025, 22:30 UTC

Market Talk

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 feb. 2025, 21:40 UTC

Câștiguri

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb. 2025, 21:19 UTC

Câștiguri

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 feb. 2025, 21:13 UTC

Câștiguri

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 feb. 2025, 21:12 UTC

Câștiguri

CSL Interim Dividend US$1.30/Security

10 feb. 2025, 21:12 UTC

Câștiguri

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10 feb. 2025, 21:11 UTC

Câștiguri

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7 nov. 2024, 03:53 UTC

Market Talk

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22 oct. 2024, 22:53 UTC

Market Talk

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10 oct. 2024, 22:20 UTC

Market Talk

CSL Bull Looking for Update on Gross Margin -- Market Talk

13 aug. 2024, 00:33 UTC

Market Talk

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12 aug. 2024, 22:34 UTC

Câștiguri

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12 aug. 2024, 22:18 UTC

Câștiguri

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12 aug. 2024, 22:18 UTC

Câștiguri

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12 aug. 2024, 22:17 UTC

Câștiguri

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12 aug. 2024, 22:16 UTC

Câștiguri

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12 aug. 2024, 22:15 UTC

Câștiguri

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12 aug. 2024, 22:14 UTC

Câștiguri

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12 aug. 2024, 22:13 UTC

Câștiguri

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12 aug. 2024, 22:13 UTC

Câștiguri

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12 aug. 2024, 22:11 UTC

Câștiguri

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12 aug. 2024, 22:10 UTC

Câștiguri

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12 aug. 2024, 22:09 UTC

Câștiguri

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12 aug. 2024, 22:08 UTC

Câștiguri

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12 aug. 2024, 22:07 UTC

Câștiguri

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

Comparație

Modificare preț

CSL Ltd Așteptări

Obiectiv de preț

By TipRanks

26.05% sus

Prognoză pe 12 luni

Medie 317.092 AUD  26.05%

Maxim 360.3 AUD

Minim 250 AUD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCSL Ltd - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

14 ratings

12

Cumpărare

2

Păstrare

0

Vânzare

Sentiment

By Acuity

121 / 468 Clasament în Sectorul industrial

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.